Daiichi Sankyo Aims for Cancer Drug Growth
Archived Content: This article was published over 30 days ago. Travel rules and prices may have changed.Check official sources.
Daiichi Sankyo plans to double oncology revenue by 2030. The Japanese drugmaker aims to be a top 5 global oncology player by 2035.
While seemingly unrelated to travel, advancements in healthcare can indirectly impact your experience in Japan. A strong pharmaceutical sector contributes to the overall health and well-being of the population, potentially affecting the availability of medical services and supplies for tourists.
Daiichi Sankyo's focus on oncology drug development signifies a commitment to innovation and healthcare advancement within Japan. This investment could lead to improved medical infrastructure and access to cutting-edge treatments.
For travelers, this means potentially greater peace of mind knowing that Japan continues to invest in its healthcare system. While you hopefully won't need it, a robust healthcare sector is always a reassuring factor when traveling abroad.
Original source:The Japan Times ↗
More Japan News
Will heat waves push European holidaymakers to ‘coolcations’?
The concept of "coolcations" — vacations in a cooler clime — has been gathering pace in recent years and appears to have exploded in 2026.
U.S. holds fire against Iran as reports emerge of stockpile concerns
The pause could reflect pressure on stockpiles of Patriot interceptors and other defensive weapons, U.S. media reports said.
Family Mart’s new Famima flagship in Tokyo has a hidden gem that most visitors miss
A must-try convenience store drink you won’t find anywhere else. Earlier this month, Family Mart shook up the convenience store scene by opening its first-ever flagship store, Famima Park Azabudai. Lo